Compare CRSP & TREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | TREX |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 3.9B |
| IPO Year | 2016 | 1998 |
| Metric | CRSP | TREX |
|---|---|---|
| Price | $54.91 | $49.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 17 |
| Target Price | ★ $70.29 | $49.53 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | $289,590,000.00 | ★ $1,174,267,000.00 |
| Revenue This Year | $807.72 | $5.09 |
| Revenue Next Year | $172.52 | $6.24 |
| P/E Ratio | ★ N/A | $86.21 |
| Revenue Growth | ★ 9169.85 | 1.98 |
| 52 Week Low | $44.12 | $29.77 |
| 52 Week High | $78.48 | $68.78 |
| Indicator | CRSP | TREX |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 66.79 |
| Support Level | $50.17 | $49.55 |
| Resistance Level | $60.10 | $54.30 |
| Average True Range (ATR) | 2.57 | 2.26 |
| MACD | 0.19 | 0.46 |
| Stochastic Oscillator | 60.16 | 95.76 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.